Viruses 2011, 3(10), 1800-1814; doi:10.3390/v3101800
Review

Next-Generation Dengue Vaccines: Novel Strategies Currently Under Development

1,* email and 2email
Received: 16 August 2011; in revised form: 20 September 2011 / Accepted: 20 September 2011 / Published: 26 September 2011
(This article belongs to the Special Issue Recent Progress in Dengue Virus Research)
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract: Dengue has become the most important arboviral infection worldwide with more than 30 million cases of dengue fever estimated to occur each year. The need for a dengue vaccine is great and several live attenuated dengue candidate vaccines are proceeding through clinical evaluation. The need to induce a balanced immune response against all four DENV serotypes with a single vaccine has been a challenge for dengue vaccine developers. A live attenuated DENV chimeric vaccine produced by Sanofi Pasteur has recently entered Phase III evaluation in numerous dengue-endemic regions of the world. Viral interference between serotypes contained in live vaccines has required up to three doses of the vaccine be given over a 12-month period of time. For this reason, novel DENV candidate vaccines are being developed with the goal of achieving a protective immune response with an immunization schedule that can be given over the course of a few months. These next-generation candidates include DNA vaccines, recombinant adenovirus vectored vaccines, alphavirus replicons, and sub-unit protein vaccines. Several of these novel candidates will be discussed.
Keywords: Dengue vaccine; DNA vaccine; vectored-vaccine; sub-unit protein vaccine
PDF Full-text Download PDF Full-Text [267 KB, uploaded 26 September 2011 18:00 CEST]

Export to BibTeX |
EndNote


MDPI and ACS Style

Durbin, A.P.; Whitehead, S.S. Next-Generation Dengue Vaccines: Novel Strategies Currently Under Development. Viruses 2011, 3, 1800-1814.

AMA Style

Durbin AP, Whitehead SS. Next-Generation Dengue Vaccines: Novel Strategies Currently Under Development. Viruses. 2011; 3(10):1800-1814.

Chicago/Turabian Style

Durbin, Anna P.; Whitehead, Stephen S. 2011. "Next-Generation Dengue Vaccines: Novel Strategies Currently Under Development." Viruses 3, no. 10: 1800-1814.


Viruses EISSN 1999-4915 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert